Syndax Pharmaceuticals: Q4 Earnings Insights
Syndax Pharmaceuticals: Q4 Earnings Insights
Shares of Syndax Pharmaceuticals (NASDAQ:SNDX) were flat in after-market trading after the company reported Q4 results.
Quarterly Results
Earnings per share increased 0.00% year over year to ($0.44), which beat the estimate of ($0.49).
Revenue of $380,000 unchanged by 0.00% from the same period last year, which beat the estimate of $200,000.
Guidance
Syndax Sees Q1 2021 R&D Expenses $25M-$30M; Sees Total Operating Expenses $30M-$35M
Syndax Pharmaceuticals Sees FY 2021 R&D Expenses $90M-$100M; Sees FY 2021 Total Operating Expenses $110M-$120M
Conference Call Details
Date: Mar 08, 2021
Time: 04:30 PM
ET Webcast URL: https://edge.media-server.com/mmc/p/wdaqmgg3
Recent Stock Performance
52-week high: $27.85
Company's 52-week low was at $6.88
Price action over last quarter: Up 22.96%
Company Overview
Syndax Pharmaceuticals Inc is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidate are entinostat which has direct effects on both cancer cells and immune regulatory cells, and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States.
Shares of Syndax Pharmaceuticals (NASDAQ:SNDX) were flat in after-market trading after the company reported Q4 results.
的股份Syndax製藥公司(納斯達克:SNDX)在盤後交易中持平,此前該公司公佈了第四季度業績。
Quarterly Results
季度業績
Earnings per share increased 0.00% year over year to ($0.44), which beat the estimate of ($0.49).
每股收益同比增長0.00%,至0.44美元,超過預期的0.49美元。
Revenue of $380,000 unchanged by 0.00% from the same period last year, which beat the estimate of $200,000.
營收為38萬美元,與去年同期持平0.00%,超過預期的20萬美元。
Guidance
導向
Syndax Sees Q1 2021 R&D Expenses $25M-$30M; Sees Total Operating Expenses $30M-$35M
Syndax Pharmaceuticals Sees FY 2021 R&D Expenses $90M-$100M; Sees FY 2021 Total Operating Expenses $110M-$120M
Syndax預計2021年第一季度研發費用為2500萬至3000萬美元;預計總運營費用為3000萬至3500萬美元Syndax製藥公司預計2021財年研發費用為9000萬至1億美元;預計2021財年總運營費用為1.1億至1.2億美元
Conference Call Details
電話會議詳細信息
Date: Mar 08, 2021
日期:2021年3月8日
Time: 04:30 PM
時間:下午4時30分
ET Webcast URL: https://edge.media-server.com/mmc/p/wdaqmgg3
Recent Stock Performance
近期股市表現
52-week high: $27.85
52周高點:27.85美元
Company's 52-week low was at $6.88
該公司52周低點為6.88美元
Price action over last quarter: Up 22.96%
上季度價格走勢:上漲22.96%
Company Overview
公司概述
Syndax Pharmaceuticals Inc is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidate are entinostat which has direct effects on both cancer cells and immune regulatory cells, and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States.
Syndax製藥公司是一家臨牀階段的生物製藥公司,專注於開發多種癌症適應症的聯合療法流水線。該公司的候選產品是Eninostat,它對癌細胞和免疫調節細胞都有直接影響,以及SNDX-6352,它是一種抗CSF-1R單克隆抗體,可以增強人體對免疫治療敏感的腫瘤的免疫反應。該集團的業務活動主要通過美國地區運作。
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧